Psilocybin
Breaking News: Quebec First Province to Cover Costs of Psilocybin Therapy
The article Breaking News: Quebec First Province to Cover Costs of Psilocybin Therapy was originally published on Microdose.
Quebec doctors have successfully…
The article Breaking News: Quebec First Province to Cover Costs of Psilocybin Therapy was originally published on Microdose.
Quebec doctors have successfully billed the province for psilocybin-assisted psychotherapy. In this Canadian-first, treatment for psychedelic therapy has been covered by the government health care system.
Back in May, Mindspace by Numinus became the first healthcare facility in Quebec to legally treat depression with psilocybin. Now we’ve received the news that these groundbreaking doctors have completed the therapy sessions and successfully billed the government to cover the cost of these services.
Kudos to non-profit Therapsil for breaking the news.
BREAKING: Quebec first province to cover costs of psilocybin-assisted psychotherapy, done by two physicians
Two doctors successfully billed for and were paid by the province of Quebec after completing psilocybin-assisted psychotherapy treatment for a patient with legal access pic.twitter.com/8CdYI10i9D
— TheraPsil (@TheraPsil) December 13, 2022
This is all part of the ongoing effort to remove legal barriers to psychedelic therapy.
Last month, TheraPsil traveled to Ottawa with patients and healthcare professionals to protest and attempt to meet with federal health ministers Jean-Yves Duclos and Carolyn Bennett to advocate for increased access. While this summer, Therapsil was part of a potentially historic lawsuit against the Minister of Health and Canadian government, arguing that patient access to psilocybin therapy is a right under the Canadian charter.
This news, although part of a larger and likely much longer fight, is a positive step forward in securing access to critical therapies for patients in need.
Interested in more on this? Check out Health Canada Approves First Special Access Request for Psilocybin and Therapsil Sues Canadian Government Over Psilocybin Access
-
Psychedelics7 days agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days agoAre Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week agoNuminus reports declining revenue as the company restructures
-
Law & Regulation7 days agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics7 days agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics6 days agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation5 days agoClearmind signs agreement with Hebrew University for psychedelic compound rights